Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label…

Overview of attention for article published in Investigational New Drugs, March 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 11 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 139 followers.

弊社にてお手伝いしました論文が掲載されました。 https://t.co/TQXXLNKp7X #論文投稿 #投稿代行 #パブリケーション #メディカルライティング

21 Mar 2023

Reply Repost Favourite

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study https://t.co/41azVZvtUg

14 Mar 2023

Reply Repost Favourite

09 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.